浅析胺碘酮治疗老年慢性心衰并室性心律失常的临床疗效

Clinical Analysis of Amiodarone in the Treatment of Senile Chronic Heart Failure and Ventricular Arrhythmia

目的研讨老年慢性心衰(CHF)并室性心律失常(VA)患者接受胺碘酮治疗的临床药效与安全性。方法以2012年1月至2017年1月在我院接受治疗的150例老年CHF并VA患者为观察对象,依照随机非盲法对其进行分组,其中Ⅰ组接受常规基础治疗,Ⅱ组在上述治疗下接受胺碘酮用药,1个疗程后,对比观察两组的临床药效、药品相关性不良反应发生率,同时对不同时间段的左室射血分数(LVEF)、左心室舒张末期内径(LVDd)及心电图变化情况做评估。结果Ⅱ组的治疗总有效率为86.7%,与Ⅰ组的总有效率(62.7%)相比,差异有统计学意义(P<0.05)。治疗后,Ⅱ组的HR、LVEF及QTc间期相比Ⅰ组均有明显的改善,比较差异有统计学意义(P<0.05);两组观察期间的药品相关性副反应发生率相比,Ⅰ组为6.7%,Ⅱ组为9.3%,比较差异无统计学意义(P>0.05)。结论胺碘酮对老年CHF并VA患者的治疗有确切的临床药效,且安全性有保障,能够明显改善患者的心功能,可作为今后治疗该心脏病的一种首选药物。

Objective To study the clinical efficacy and safety of amiodarone in elderly patients with chronic heart failure(CHF) and ventricular arrhythmia(VA). Methods 150 patients with CHF and VA who underwent treatment in our hospital from January 2012 to January 2017 were enrolled in this study according to the randomized nonblind method. Group Ⅰ received routine basic therapy, group Ⅱ(LVEF), left ventricular end-diastolic phase(LVEF), left ventricular ejection fraction(LVEF), left ventricular ejection fraction(LVEF), left ventricular ejection fraction(LVEF), left ventricular ejection fraction(LVEF), left ventricular endocytosis(LVDd) and electrocardiogram were evaluated. Results The total effective rate of group Ⅱ was 86.7%, compared with the total effective rate of group I(62.7%), the difference was statistically significant(P<0.05). After treatment, the levels of HR, LVEF and QTc in group Ⅱ were significantly improved compared with those in group Ⅰ(P<0.05). The incidence of drug-related side effects during the two groups was 6.7%, group 9.3%, the difference was not statistically significant(P>0.05). Conclusion Amiodarone has definite clinical efficacy in the treatment of elderly patients with CHF and VA, and it is safe and can improve the cardiac function of patients. It can be used as a preferred drug for the treatment of heart disease in the future.